<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20250110051145&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20250110051145&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 10 Jan 2025 10:11:45 +0000</lastbuilddate>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39788123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>As the brain transitions from wakefulness to sleep, processing of external information diminishes while restorative processes, such as glymphatic removal of waste products, are activated. Yet, it is not known what drives brain clearance during sleep. We here employed an array of technologies and identified tightly synchronized oscillations in norepinephrine, cerebral blood volume, and cerebrospinal fluid (CSF) as the strongest predictors of glymphatic clearance during NREM sleep. Optogenetic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 17:S0092-8674(24)01343-6. doi: 10.1016/j.cell.2024.11.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">As the brain transitions from wakefulness to sleep, processing of external information diminishes while restorative processes, such as glymphatic removal of waste products, are activated. Yet, it is not known what drives brain clearance during sleep. We here employed an array of technologies and identified tightly synchronized oscillations in norepinephrine, cerebral blood volume, and cerebrospinal fluid (CSF) as the strongest predictors of glymphatic clearance during NREM sleep. Optogenetic stimulation of the locus coeruleus induced anti-correlated changes in vasomotion and CSF signal. Furthermore, stimulation of arterial oscillations enhanced CSF inflow, demonstrating that vasomotion acts as a pump driving CSF into the brain. On the contrary, the sleep aid zolpidem suppressed norepinephrine oscillations and glymphatic flow, highlighting the critical role of norepinephrine-driven vascular dynamics in brain clearance. Thus, the micro-architectural organization of NREM sleep, driven by norepinephrine fluctuations and vascular dynamics, is a key determinant for glymphatic clearance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39788123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39788123</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.027>10.1016/j.cell.2024.11.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39788123</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Natalie L Hauglund</dc:creator>
<dc:creator>Mie Andersen</dc:creator>
<dc:creator>Klaudia Tokarska</dc:creator>
<dc:creator>Tessa Radovanovic</dc:creator>
<dc:creator>Celia Kjaerby</dc:creator>
<dc:creator>Frederikke L Sørensen</dc:creator>
<dc:creator>Zuzanna Bojarowska</dc:creator>
<dc:creator>Verena Untiet</dc:creator>
<dc:creator>Sheyla B Ballestero</dc:creator>
<dc:creator>Mie G Kolmos</dc:creator>
<dc:creator>Pia Weikop</dc:creator>
<dc:creator>Hajime Hirase</dc:creator>
<dc:creator>Maiken Nedergaard</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep</dc:title>
<dc:identifier>pmid:39788123</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.027</dc:identifier>
</item>
<item>
<title>Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this European cohort, the lifetime risk of developing HFrEF was greater in men than in women, while women were at greater risk of developing HFpEF. Eight directly and indirectly modifiable risk factors substantially accounted for the risk of developing HFrEF and HFpEF, particularly in women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae868. doi: 10.1093/eurheartj/ehae868. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current estimates for the lifetime risk to develop heart failure with either a reduced (HFrEF) or preserved ejection fraction (HFpEF) and their associated risk factors are derived from two studies from the USA. The sex-specific lifetime risk and population attributable fraction of potentially modifiable risk factors for incident HFpEF and HFrEF are described in a large European community-based cohort with 25 years of follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 8558 participants from the PREVEND cohort were studied at baseline from 1997 onwards and followed until 2022 for cases of new-onset HFrEF (ejection fraction &lt; 50%) and HFpEF (ejection fraction ≥ 50%) by assessment of hospital records.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 804 cases of new-onset HF were identified (534 HFrEF and 270 HFpEF) during 25 years of follow-up. The mean age at baseline was 50 years for men and 47 years for women. The mean age at onset of HF was 72.1 years in men and 74.2 years in women. The overall lifetime risk of developing HF was 24.5% in men compared to 23.3% in women. The lifetime risk of HFrEF was lower in women compared with men (11.9% vs. 18.1%), while the lifetime risk of HFpEF was higher in women compared with men (11.5% vs. 6.4%). In women, 71% of incident HFrEF cases were attributable to eight risk factors (hypertension, hypercholesterolaemia, obesity, smoking, atrial fibrillation, chronic kidney disease, myocardial infarction, and diabetes mellitus) and 60% in men. In women, 64% of incident HFpEF cases were attributable to those risk factors, whereas this was 46% in men. More specifically, in both men and women, hypertension and hypercholesterolaemia were the strongest risk factors for HFrEF, whereas hypertension and obesity were the strongest risk factors for HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this European cohort, the lifetime risk of developing HFrEF was greater in men than in women, while women were at greater risk of developing HFpEF. Eight directly and indirectly modifiable risk factors substantially accounted for the risk of developing HFrEF and HFpEF, particularly in women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786471</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae868>10.1093/eurheartj/ehae868</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786471</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Bart J van Essen</dc:creator>
<dc:creator>Johanna E Emmens</dc:creator>
<dc:creator>Jasper Tromp</dc:creator>
<dc:creator>Wouter Ouwerkerk</dc:creator>
<dc:creator>Marcelle D Smit</dc:creator>
<dc:creator>Christiane A Geluk</dc:creator>
<dc:creator>Lukas Baumhove</dc:creator>
<dc:creator>Navin Suthahar</dc:creator>
<dc:creator>Ron T Gansevoort</dc:creator>
<dc:creator>Stephan J L Bakker</dc:creator>
<dc:creator>Kevin Damman</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years</dc:title>
<dc:identifier>pmid:39786471</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae868</dc:identifier>
</item>
<item>
<title>Hospitalized upper extremity artery disease patients: treatment and long-term outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Upper extremity artery disease patients, irrespective of the underlying disease type, face a poor prognosis with elevated proportion of amputation and mortality. Male sex was linked to increased risk of future cardiovascular and limb events including death. Further investigation is warranted to understand the underlying causes of the sex-related disparities and identify treatment improvements.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae904. doi: 10.1093/eurheartj/ehae904. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current knowledge about upper extremity artery disease (UEAD) is scarce. This study aimed to evaluate the prevalence, treatment patterns, and short- and long-term outcomes of patients suffering from UEAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Retrospective health claims data of patients who were hospitalized with a primary diagnosis of UEAD between 2010 and 2017 were analysed. The data were obtained from 11 legally independent statutory health insurance funds of the 'AOK-Die Gesundheitskasse'. Risk factors, comorbidities, pharmacotherapy, revascularization procedure, and outcome were evaluated with a particular focus on sex-related disparities (median follow-up time: 5.5 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2437 UEAD patients (43% female, median age of 67 years), 80% were solely atherosclerotic (UEADa), while 20% had concomitant inflammatory/connective tissue diseases (UEADc/i). Cardiovascular risk factors and comorbidities were highly prevalent in both sexes. Coronary, cerebrovascular, and lower extremity artery diseases and organ failure such as chronic kidney and heart failure were more frequent in men compared with women. At index stay, women had higher rate of revascularization than men (37% vs. 27%). The 5 year mortality among the entire population was almost 50%, even higher in men (UEADa: 51% vs. 36% P &lt; .001; UEADc/i: 44% vs. 36%, P &lt; .05). Furthermore, men had higher rates of upper limb amputation compared with women despite equal secondary preventive pharmacotherapy (UEADa: 26% vs. 11%, P &lt; .001; UEADc/i: 30% vs. 18%, P &lt; .01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Upper extremity artery disease patients, irrespective of the underlying disease type, face a poor prognosis with elevated proportion of amputation and mortality. Male sex was linked to increased risk of future cardiovascular and limb events including death. Further investigation is warranted to understand the underlying causes of the sex-related disparities and identify treatment improvements.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786470</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae904>10.1093/eurheartj/ehae904</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786470</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lena Makowski</dc:creator>
<dc:creator>Christiane Engelbertz</dc:creator>
<dc:creator>Jeanette Köppe</dc:creator>
<dc:creator>Patrik Dröge</dc:creator>
<dc:creator>Thomas Ruhnke</dc:creator>
<dc:creator>Christian Günster</dc:creator>
<dc:creator>Joachim Gerß</dc:creator>
<dc:creator>Eva Freisinger</dc:creator>
<dc:creator>Nasser Malyar</dc:creator>
<dc:creator>Holger Reinecke</dc:creator>
<dc:creator>Jannik Feld</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hospitalized upper extremity artery disease patients: treatment and long-term outcomes</dc:title>
<dc:identifier>pmid:39786470</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae904</dc:identifier>
</item>
<item>
<title>Multiple simultaneous coronary plaque erosion detected by optical coherence tomography associated with systemic lupus erythematosus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae899. doi: 10.1093/eurheartj/ehae899. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786444</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae899>10.1093/eurheartj/ehae899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786444</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lina Cui</dc:creator>
<dc:creator>Chao Fang</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multiple simultaneous coronary plaque erosion detected by optical coherence tomography associated with systemic lupus erythematosus</dc:title>
<dc:identifier>pmid:39786444</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae899</dc:identifier>
</item>
<item>
<title>Mechanism of syncope: role of ambulatory blood pressure monitoring and cardiovascular autonomic function assessment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The standardized 2STEPS protocol offers an easy-to-perform and time-saving diagnostic work-up allowing identification of the haemodynamic mechanism of loss of consciousness in most patients with autonomic syncope. This protocol provides the necessary background for a personalized mechanism-specific therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae907. doi: 10.1093/eurheartj/ehae907. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identifying the haemodynamic mechanism of autonomic syncope is the essential pre-requisite for effective and personalized therapy aimed at preventing recurrences. The present study assessed the diagnostic efficacy of a two-step assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Multicentre prospective, cross-sectional, observational study. Patients affected by severe autonomic syncope underwent a two-step assessment including 24-h ambulatory blood pressure monitoring and short cardiovascular autonomic function assessment (SCAFA). SCAFA consisted of carotid sinus massage (CSM), performed in patients ≥40 years old, a passive standing test, and a 'fast' head-up tilt test scheduled sequentially during one session on a tilt table.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 333 patients, 102 ≤ 40 years old and 231 >; 40 years old. Any positive response was observed in 298 (89%) patients (92 [92%] in younger and 134 [89%] in older), with hypotensive phenotype accounting for 226 (68%), bradycardic phenotype for 21 (6%) and mixed phenotype for 51 (15%) of cases. The mean duration of the SCAFA procedure was 25 (IQR 20-32) min. Ambulatory blood pressure monitoring, CSM, passive standing, and head-up tilt test were positive in 60%, 15%, 3%, and 71% of patients, respectively. More than one test was positive in 51% and 49% of patients ≤40 and >;40 years, respectively. Large inter-centre variability of CSM positivity rate, which remained significant after adjustment for demographic and clinical variables, was observed (P = .003).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The standardized 2STEPS protocol offers an easy-to-perform and time-saving diagnostic work-up allowing identification of the haemodynamic mechanism of loss of consciousness in most patients with autonomic syncope. This protocol provides the necessary background for a personalized mechanism-specific therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786439</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae907>10.1093/eurheartj/ehae907</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786439</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Antonella Groppelli</dc:creator>
<dc:creator>Vincenzo Russo</dc:creator>
<dc:creator>Erika Parente</dc:creator>
<dc:creator>Angelo Comune</dc:creator>
<dc:creator>Frederik J de Lange</dc:creator>
<dc:creator>Giulia Rivasi</dc:creator>
<dc:creator>Martina Rafanelli</dc:creator>
<dc:creator>Jean Claude Deharo</dc:creator>
<dc:creator>Jaume Francisco-Pascual</dc:creator>
<dc:creator>Roberto Maggi</dc:creator>
<dc:creator>Artur Fedorowski</dc:creator>
<dc:creator>Andrea Ungar</dc:creator>
<dc:creator>Gianfranco Parati</dc:creator>
<dc:creator>Michele Brignole</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mechanism of syncope: role of ambulatory blood pressure monitoring and cardiovascular autonomic function assessment</dc:title>
<dc:identifier>pmid:39786439</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae907</dc:identifier>
</item>
<item>
<title>Rate dependent complete right bundle block: a challenging diagnosis in Brugada syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae921. doi: 10.1093/eurheartj/ehae921. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786427</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae921>10.1093/eurheartj/ehae921</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786427</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jing Yang</dc:creator>
<dc:creator>Rong He</dc:creator>
<dc:creator>Ping Zhang</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rate dependent complete right bundle block: a challenging diagnosis in Brugada syndrome</dc:title>
<dc:identifier>pmid:39786427</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae921</dc:identifier>
</item>
<item>
<title>Recurrent plaque erosion is linked to biomechanical conditions: insight from optical coherence tomography-based fluid-structure interaction models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786425/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 30:ehae903. doi: 10.1093/eurheartj/ehae903. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786425/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786425</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae903>10.1093/eurheartj/ehae903</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786425</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Haibo Jia</dc:creator>
<dc:creator>Liang Wang</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Recurrent plaque erosion is linked to biomechanical conditions: insight from optical coherence tomography-based fluid-structure interaction models</dc:title>
<dc:identifier>pmid:39786425</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae903</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786152/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae897. doi: 10.1093/eurheartj/ehae897. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786152/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786152</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae897>10.1093/eurheartj/ehae897</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786152</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarction</dc:title>
<dc:identifier>pmid:39786152</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae897</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: the (BP)ROAD to optimal blood pressure control in type-2 diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39786145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae894. doi: 10.1093/eurheartj/ehae894. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39786145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39786145</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae894>10.1093/eurheartj/ehae894</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39786145</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: the (BP)ROAD to optimal blood pressure control in type-2 diabetes</dc:title>
<dc:identifier>pmid:39786145</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae894</dc:identifier>
</item>
<item>
<title>Coronary revascularization in the NOTION-2 trial: an in-depth data analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae763. doi: 10.1093/eurheartj/ehae763. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39783784</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae763>10.1093/eurheartj/ehae763</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783784</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary revascularization in the NOTION-2 trial: an in-depth data analysis</dc:title>
<dc:identifier>pmid:39783784</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae763</dc:identifier>
</item>
<item>
<title>Coronary revascularization in randomized clinical trials comparing transcatheter and surgical aortic valve replacement: is it time to bridge the gap?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783766/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae762. doi: 10.1093/eurheartj/ehae762. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783766/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39783766</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae762>10.1093/eurheartj/ehae762</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783766</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hugo M Aarts</dc:creator>
<dc:creator>Michiel Voskuil</dc:creator>
<dc:creator>Ronak Delewi</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary revascularization in randomized clinical trials comparing transcatheter and surgical aortic valve replacement: is it time to bridge the gap?</dc:title>
<dc:identifier>pmid:39783766</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae762</dc:identifier>
</item>
<item>
<title>Non-oncologic metastases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae211. doi: 10.1093/eurheartj/ehae211. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39783660</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae211>10.1093/eurheartj/ehae211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783660</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dina Fernandes Neto</dc:creator>
<dc:creator>Maria Melendo-Viu</dc:creator>
<dc:creator>Cristina Gomez-Varela</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-oncologic metastases</dc:title>
<dc:identifier>pmid:39783660</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae211</dc:identifier>
</item>
<item>
<title>PIEZO1 as a potential therapeutic target in Marfan syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39783624/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 9:ehae882. doi: 10.1093/eurheartj/ehae882. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39783624/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39783624</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae882>10.1093/eurheartj/ehae882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39783624</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jin Komuro</dc:creator>
<dc:creator>Norifumi Takeda</dc:creator>
<dc:creator>Issei Komuro</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>PIEZO1 as a potential therapeutic target in Marfan syndrome</dc:title>
<dc:identifier>pmid:39783624</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae882</dc:identifier>
</item>
<item>
<title>Impact of Heart Transplant Allocation Changes on Waitlist Mortality and Clinical Practice in Pediatric and Adult Patients With Congenital Heart Disease and Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39781913/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The recent allocation changes of the Organ Procurement and Transplantation Network associations with waitlist duration and outcome were not uniform across pediatric and adult cohorts with CHD or those with cardiomyopathy. Children with cardiomyopathy and adults with CHD did not experience the mortality benefits experienced by adults with cardiomyopathy and children with CHD. Future iterations of the allocation systems should consider differential access to mechanical circulatory...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 9. doi: 10.1161/CIRCULATIONAHA.124.072335. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The United Network of Organ Sharing made changes to the priority for allocation of hearts for transplantation (HT) in 2016 for pediatric patients and 2018 for adult patients. Although recent work has evaluated the impact of the revised allocation systems on mechanical circulatory support practices and waitlist outcomes, there are limited data that focus more specifically on the impact of the allocation changes on patients with congenital heart disease (CHD) or cardiomyopathy and how these relationships might differ in pediatric and adult patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The United Network of Organ Sharing database was queried for pediatric (&lt;18 years of age) and adult (18-50 years of age) patients with a CHD or cardiomyopathy diagnosis listed for HT. Cohorts were grouped into preallocation and postallocation change eras: pediatric patients from January 1, 2011, to March 21, 2016, and January 1, 2017, to December 31, 2021; and adult patients from January 1, 2015, to October 17, 2018, and January 1, 2019, to December 31, 2021. Differences in era for survival or waitlist removal because of clinical deterioration from the time of HT listing were compared using competing risk models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 11 637 patients listed for HT during the study period, including 2882 pediatric patients with CHD, 594 adults with CHD, 2348 pediatric patients with cardiomyopathy, and 5813 adults with cardiomyopathy. In a competing risk model adjusting for demographic and clinical factors, allocation changes were significantly associated with lower death or waitlist removal within 1 year of HT listing in infants with CHD (HR, 0.75 [0.57-0.99]; <i>P</i>=0.04), children with CHD (HR, 0.61 [0.43-0.86]; <i>P</i>=0.005), and adults with cardiomyopathy (HR, 0.60 [0.44-0.81]; <i>P</i>=0.001), but not in infants with cardiomyopathy, children with cardiomyopathy, or adults with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The recent allocation changes of the Organ Procurement and Transplantation Network associations with waitlist duration and outcome were not uniform across pediatric and adult cohorts with CHD or those with cardiomyopathy. Children with cardiomyopathy and adults with CHD did not experience the mortality benefits experienced by adults with cardiomyopathy and children with CHD. Future iterations of the allocation systems should consider differential access to mechanical circulatory support options for children and adults, patient sensitization status, and whether having separate systems for adults and children is the most appropriate method to allocate organs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39781913/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39781913</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072335>10.1161/CIRCULATIONAHA.124.072335</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39781913</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Luke Wooster</dc:creator>
<dc:creator>Matthew J O'Connor</dc:creator>
<dc:creator>Xuemei Zhang</dc:creator>
<dc:creator>Constantine D Mavroudis</dc:creator>
<dc:creator>Katsuhide Maeda</dc:creator>
<dc:creator>Humera Ahmed</dc:creator>
<dc:creator>Jonathan Edwards</dc:creator>
<dc:creator>Kimberly Y Lin</dc:creator>
<dc:creator>Carol Wittlieb-Weber</dc:creator>
<dc:creator>Joseph Rossano</dc:creator>
<dc:creator>Jonathan B Edelson</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impact of Heart Transplant Allocation Changes on Waitlist Mortality and Clinical Practice in Pediatric and Adult Patients With Congenital Heart Disease and Cardiomyopathy</dc:title>
<dc:identifier>pmid:39781913</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072335</dc:identifier>
</item>
<item>
<title>Prevalence and Clinical Outcomes of Discordant Lesions Between Fractional Flow Reserve and Nonhyperemic Pressure Ratios in Clinical Practice: The J-PRIDE Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39781739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Discordance between FFR and NHPRs was noted in 20% of lesions, and discordant deferred lesions resulted in worse outcomes than concordant negative lesions. Although the outcomes after deferring revascularization were comparable between the FFR+/NHPR- and FFR-/NHPR+ lesions, only FFR+/NHPR- lesions showed a benefit from revascularization compared with medical treatment, suggesting that an FFR-guided strategy is superior to an NHPR-guided strategy in discordant lesions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 9. doi: 10.1161/CIRCULATIONAHA.124.071139. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited large-scale, real-world data exist on the prevalence and clinical impact of discordance between fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The J-PRIDE registry (Clinical Outcomes of Japanese Patients With Coronary Artery Disease Assessed by Resting Indices and Fractional Flow Reserve: A Prospective Multicenter Registry) prospectively enrolled 4304 lesions in 3200 patients from 20 Japanese centers. The lesions were classified into FFR+/NHPR-, FFR-/NHPR+, FFR+/NHPR+, or FFR-/NHPR groups according to cutoff values of 0.89 for NHPRs and 0.80 for FFR. The primary study end point was the cumulative 1-year incidence of target vessel failure (a composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization) on a lesion basis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: An NHPR cutoff value of 0.89, determined using online software, predicted an FFR of 0.80 across various NHPR types. Discordance between FFR and NHPRs was observed in 20% of lesions (FFR+/NHPR-, 11.2%; FFR-/NHPRs+, 8.8%). Revascularization was deferred in 42.9% and 88.4% of the FFR+/NHPR- and FFR-/NHPR+ groups, respectively. In deferred vessels, the FFR+/NHPR- and FFR-/NHPR+ groups showed a higher 1-year incidence of target vessel failure compared with the FFR-/NHPR- group (7.9% versus 5.5% versus 1.7%; for FFR+/NHPR-, adjusted hazard ratio [aHR], 4.89 [95% CI, 2.68-8.91]; <i>P</i>&lt;0.001; for FFR-/NHPR+, aHR, 2.64 [95% CI, 1.49-4.69]; <i>P</i>&lt;0.001). In revascularized vessels, the 1-year target vessel failure rate was numerically higher in the FFR-/NHPR+ group than in the FFR+/NHPR+ group (9.6% versus 3.4%; aHR, 2.27 [95% CI, 0.70-7.34]; <i>P</i>=0.17), although with similar outcomes between the FFR+/NHPR- and FFR+/NHPR+ groups (2.3% versus 3.4%; aHR, 0.96 [95% CI, 0.37-2.38]; <i>P</i>=0.93). The FFR+/NHPR- group benefited from revascularization compared with medical treatment (aHR, 0.26 [95% CI, 0.08-0.86]; <i>P</i>=0.027); the FFR-/NHPR+ group did not (aHR, 2.39 [95% CI, 0.62-9.21]; <i>P</i>=0.20).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Discordance between FFR and NHPRs was noted in 20% of lesions, and discordant deferred lesions resulted in worse outcomes than concordant negative lesions. Although the outcomes after deferring revascularization were comparable between the FFR+/NHPR- and FFR-/NHPR+ lesions, only FFR+/NHPR- lesions showed a benefit from revascularization compared with medical treatment, suggesting that an FFR-guided strategy is superior to an NHPR-guided strategy in discordant lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.umin.ac.jp; Unique identifier: UMIN000038403.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39781739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39781739</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071139>10.1161/CIRCULATIONAHA.124.071139</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39781739</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shoichi Kuramitsu</dc:creator>
<dc:creator>Yoshiaki Kawase</dc:creator>
<dc:creator>Tomohiro Shinozaki</dc:creator>
<dc:creator>Takenori Domei</dc:creator>
<dc:creator>Futoshi Yamanaka</dc:creator>
<dc:creator>Umihiko Kaneko</dc:creator>
<dc:creator>Tsunekazu Kakuta</dc:creator>
<dc:creator>Kazunori Horie</dc:creator>
<dc:creator>Hidenobu Terai</dc:creator>
<dc:creator>Hirohiko Ando</dc:creator>
<dc:creator>Yasutsugu Shiono</dc:creator>
<dc:creator>Toru Tagashira</dc:creator>
<dc:creator>Kazutaka Nogi</dc:creator>
<dc:creator>Takashi Kubo</dc:creator>
<dc:creator>Taku Asano</dc:creator>
<dc:creator>Jun Shiraishi</dc:creator>
<dc:creator>Hiromasa Otake</dc:creator>
<dc:creator>Akinori Sugano</dc:creator>
<dc:creator>Reo Anai</dc:creator>
<dc:creator>Atsushi Iwai</dc:creator>
<dc:creator>Yuetsu Kikuta</dc:creator>
<dc:creator>Hidetaka Nishina</dc:creator>
<dc:creator>Tsutomu Fujita</dc:creator>
<dc:creator>Tetsuya Amano</dc:creator>
<dc:creator>Masashi Iwabuchi</dc:creator>
<dc:creator>Hiroyoshi Yokoi</dc:creator>
<dc:creator>Takashi Akasaka</dc:creator>
<dc:creator>Hitoshi Matsuo</dc:creator>
<dc:creator>Nobuhiro Tanaka</dc:creator>
<dc:creator>J-PRIDE Investigators</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prevalence and Clinical Outcomes of Discordant Lesions Between Fractional Flow Reserve and Nonhyperemic Pressure Ratios in Clinical Practice: The J-PRIDE Registry</dc:title>
<dc:identifier>pmid:39781739</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071139</dc:identifier>
</item>
<item>
<title>Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e9. doi: 10.1016/j.jacc.2024.10.116.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39779064</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.116>10.1016/j.jacc.2024.10.116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779064</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Suvasini Lakshmanan</dc:creator>
<dc:creator>Venkat Sanjay Manubolu</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</dc:title>
<dc:identifier>pmid:39779064</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.116</dc:identifier>
</item>
<item>
<title>How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779063/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e7. doi: 10.1016/j.jacc.2024.08.088.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779063/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39779063</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.088>10.1016/j.jacc.2024.08.088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779063</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gianluca Iacobellis</dc:creator>
<dc:creator>Alexis Elias Malavazos</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</dc:title>
<dc:identifier>pmid:39779063</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.088</dc:identifier>
</item>
<item>
<title>Reply: Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e17. doi: 10.1016/j.jacc.2024.10.115.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39779062</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.115>10.1016/j.jacc.2024.10.115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779062</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sahmin Lee</dc:creator>
<dc:creator>Jae-Kwan Song</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</dc:title>
<dc:identifier>pmid:39779062</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.115</dc:identifier>
</item>
<item>
<title>Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779061/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e15. doi: 10.1016/j.jacc.2024.09.1243.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779061/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39779061</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1243>10.1016/j.jacc.2024.09.1243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779061</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan L Ciofani</dc:creator>
<dc:creator>Ravinay Bhindi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</dc:title>
<dc:identifier>pmid:39779061</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1243</dc:identifier>
</item>
<item>
<title>Reply: Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e13. doi: 10.1016/j.jacc.2024.09.1242.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39779060</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1242>10.1016/j.jacc.2024.09.1242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779060</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rodney H Falk</dc:creator>
<dc:creator>Sarah A M Cuddy</dc:creator>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</dc:title>
<dc:identifier>pmid:39779060</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1242</dc:identifier>
</item>
<item>
<title>Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250110051145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e11-e12. doi: 10.1016/j.jacc.2024.08.087.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250110051145&v=2.18.0.post9+e462414">39779059</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.087>10.1016/j.jacc.2024.08.087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779059</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Giorgia Panichella</dc:creator>
<dc:creator>Vincenzo Castiglione</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</dc:title>
<dc:identifier>pmid:39779059</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.087</dc:identifier>
</item>





























</channel>
</rss>